Aptitude has received multi-million dollars in funding
Aptitude has received USPTO patent approval of our breakthrough Particle Display technology
Aptitude is hiring! See current openings.
Aptitude has received 5 million dollars in non-dilutive funding
Imagine a synthetic antibody that:
is highly stable, resistant to denaturing, and works on diverse platforms
binds with high affinity and specificity to intractable targets, and discriminates targets that differ by only a single functional group
accommodates site-specific modification by various functional groups, and unlocks a multitude of unique applications
Imagine a company who can turn that dream into reality.
Welcome to the reality of Aptitude.
Find out who is behind the Aptitude technology